NOME portfolio company AdaptVac will coordinate a global consortium developing a vaccine candidate targeting multiple filoviruses, including Ebolavirus Zaire, Sudan Ebolavirus and Marburg virus. The project is supported by $12.4 million in funding from CEPI and the European Union’s Horizon Europe programme.
The vaccine will combine immunogens designed using AI technology with AdaptVac’s Virus-Like-Particle platform. The goal is to create a single vaccine candidate that offers broad protection, initially tested in preclinical studies and then evaluated in Phase 1/2 trials in Gabon and the Netherlands.
The initiative aims to support equitable access, with commitments around affordable pricing and supply volumes, and to generate data that advances the 100 Days Mission — an effort to accelerate vaccine development against future epidemic and pandemic threats.